| [1] Czepiel J, Biesiada G, Mach T. Viral hepatitis C[J]. Pol Arch Med Wewn,2008,118(12):734-740.[2] Saadeh S, Davis G L. The evolving treatment of chronic hepatitis C: where we stand a decade out[J]. Cleve Clin J Med,2004,71(Suppl 3):S3-7.[3] Gryseels B, Polman K, Clerinx J, et al. Human schistosomiasis[J]. Lancet,2006,368(9541):1106-1118.[4] Aman W, Mousa S, Shiha G, et al. Current status and future directions in the management of chronic hepatitis C[J]. Virol J,2012,9:57[5] Sarasin-Filipowicz M. Interferon therapy of hepatitis C: molecular insights into success and failure[J]. Swiss Med Wkly,2010,140(1-2):3-11.[6] Di Bisceglie A M, Hoofnagle J H. Optimal therapy of hepatitis C[J]. Hepatology,2002,36(5 Suppl 1):S121-S127.[7] Seeff L B,Hoofnagle J H. National institutes of health consensus development conference: management of hepatitis C: 2002[J]. Hepatology,2002,36(5 Suppl 1):S1-S2.[8] Fried M W, Shiffman M L, Reddy K R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection[J]. N Engl J Med,2002,347(13):975-982.[9] Spiegel B M, Younossi Z M, Hays R D, et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment[J]. Hepatology,2005,41(4):790-800.[10] Zeuzem S, Feinman S V, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C[J]. N Engl J Med,2000,343(23):1666-1672.[11] Lindsay K L, Morishima C, Wright E C, et al. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C[J]. Clin Gastroenterol Hepatol,2008,6(2):234-241.[12] Hepatology of Chinese Medical Association. Infectious disease and parasitic disease branch of Chinese medical association. Guidelines for the prevention and treatment of hepatitis C[J]. Chin J Hepatol,2004,12(4):194-198. (In Chinese)[13] Janke E A, McGraw S, Garcia-Tsao G, et al. Psychosocial issues in hepatitis C: a qualitative analysis[J]. Psychosomatics,2008,49(6):494-501.[14] Zickmund S, Ho E Y, Masuda M, et al.‘They treated me like a leper’: stigmatization and the qualify of life of patients with hepatitis C[J]. J Gen Intern Med,2003,18(10):835-844.[15] McHutchison J G, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C[J]. Semin Liver Dis,1999,19 (Suppl 1):57-65.[16] Kraus M R, Schafer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy[J]. J Clin Psychiatry,2003,64(6):708-714.[17] McHutchison J G, Gordon S C, Schiff E R,et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group[J]. N Engl J Med,1998, 339(21): 1485-1492.[18] McHutchison J G, Manns M, Patel K,et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C[J]. Gastroenterology, 2002, 123(4): 1061-1069.[19] Shi H F,Jiang J D,Li LZ,et al.The research progress of patient compliance[J]. Chin J Nurs, 2003,38(2):134-136.[20] Hua R, Niu J Q. Pegylated interferon-the best choice for against hepatitis C virus[J]. J Clin Hepatol,2004,20(4):253-254.[21] Tang H M,Chen F,Yang H Y.Study on the compliance and medication satisfaction in patients receiving antiviral therapy[J].Chinese J Modern Nurs, 2013,19(2):160-162.[22] Jing X M,Li J R,Meng Q. Adverse reaction and nursing countermeasures in the interferon treatment of chronic hepatitis C[J].J North Sichuan Med Coll, 2001,16(1):69-70.[23] Miao J, Luo L S. Influence of health education for patients with embolism of hepatic artery[J]. Chin J Pract Nurs, 2007,21(7A):59-60.[24] Wang F Q,Lin X H,Liu Y W. Study for the correlation of treatment compliance for patients with chronic hepatitis C[J].J Nurs Train, 2009,24(1):13-14. |
